Tango TherapeuticsTNGX
TNGX
About: Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.
Employees: 140
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
41% more call options, than puts
Call options by funds: $24K | Put options by funds: $17K
12% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 17
2.18% more ownership
Funds ownership: 92.52% [Q2] → 94.7% (+2.18%) [Q3]
2% more funds holding
Funds holding: 119 [Q2] → 121 (+2) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 6 [Q2] → 6 (+0) [Q3]
0% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 37
8% less capital invested
Capital invested by funds: $848M [Q2] → $781M (-$66.9M) [Q3]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$8
156%
upside
Avg. target
$9.67
210%
upside
High target
$13
317%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
B. Riley Securities Yuan Zhi 22% 1-year accuracy 2 / 9 met price target | 156%upside $8 | Buy Maintained | 11 Nov 2024 |
HC Wainwright & Co. Robert Burns 23% 1-year accuracy 36 / 155 met price target | 317%upside $13 | Buy Reiterated | 8 Nov 2024 |
Guggenheim Charles Zhu 0% 1-year accuracy 0 / 2 met price target | 156%upside $8 | Buy Maintained | 7 Nov 2024 |
Financial journalist opinion
Neutral
Business Wire
2 weeks ago
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON--(BUSINESS WIRE)--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that, effective December 2, 2024, the Compensation Committee of Tango Therapeutics' Board of Directors granted a non-qualified stock option to purchase 187,500 shares of its common stock and 31,250 restricted stock units (RSUs) to a new employee under Tango Therapeutics' 2023 Inducement.
Neutral
Business Wire
3 weeks ago
Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
BOSTON--(BUSINESS WIRE)--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Adam Crystal, M.D., Ph.D., President, Research & Development of Tango Therapeutics, is scheduled to present at the Piper Sandler 36th Annual Healthcare Conference on Thursday, December 5, 2024 at 1:30 PM ET. A live webcast of the presentation will be available under the "Events.
Negative
Zacks Investment Research
1 month ago
Tango Therapeutics, Inc. (TNGX) Reports Q3 Loss, Tops Revenue Estimates
Tango Therapeutics, Inc. (TNGX) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.23 per share a year ago.
Neutral
Business Wire
1 month ago
Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights
BOSTON--(BUSINESS WIRE)--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the third quarter ended September 30, 2024, and provided business highlights. “We have made great progress with our PRMT5 development program, including positive data from the TNG462 phase 1/2 clinical trial that showcase the best-in-class potential of TNG462 in multi.
Neutral
Business Wire
1 month ago
Tango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development Program
BOSTON--(BUSINESS WIRE)--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, announced an update on its PRMT5 program. Based on positive data from the dose escalation and early dose expansion cohorts of the TNG462 phase 1/2 clinical trial, the Company has selected TNG462 to move forward into full development. TNG908, an MTA-cooperative brain penetrant PRMT5 inhibitor, is clinic.
Negative
Seeking Alpha
3 months ago
Tango Therapeutics: Amgen Missteps Devalue PRMT5 Candidates Ahead Of Critical Data
Tango Therapeutics, Inc. offers high-risk, high-reward exposure to PRMT5-inhibitor drugs, with two candidates, TNG908 and TNG462, targeting MTAP-deleted cancers, a substantial market opportunity. TNGX stock volatility is influenced by competitors' PRMT5 data, with recent fluctuations driven by Amgen and Mirati's clinical results. Tango's financial stability is supported by >$300M in cash, a Gilead partnership, and a funding runway until 2027, covering key clinical readouts.
Neutral
Business Wire
3 months ago
Tango Therapeutics to Participate in Upcoming Investor Conferences
BOSTON--(BUSINESS WIRE)--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in the following upcoming investor conferences in September. 2024 Wells Fargo Healthcare Conference Date: Wednesday, September 4, 2024 Time: 12:45 PM ET Location: Boston, M.
Negative
Zacks Investment Research
4 months ago
Tango Therapeutics, Inc. (TNGX) Reports Q2 Loss, Tops Revenue Estimates
Tango Therapeutics, Inc. (TNGX) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.23 per share a year ago.
Neutral
Business Wire
4 months ago
Tango Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights
BOSTON--(BUSINESS WIRE)--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the second quarter ended June 30, 2024, and provided business highlights. “In the second quarter, we continued to advance the dose expansion portions of the TNG908 and TNG462 phase 1/2 clinical trials. We are progressing these molecules with the intent of remaining a.
Negative
Zacks Investment Research
4 months ago
Earnings Preview: Tango Therapeutics, Inc. (TNGX) Q2 Earnings Expected to Decline
Tango Therapeutics (TNGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Charts implemented using Lightweight Charts™